文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

美国新冠疫苗第二剂完成率及接种间隔分析

COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons - United States, December 14, 2020-February 14, 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-03-19

In December 2020, two COVID-19 vaccines (Pfizer-BioNTech and Moderna) received Emergency Use Authorization from the Food and Drug Administration.*,† Both vaccines require 2 doses for a completed series.…

要点

  • 有足够时间接种第二剂者中88.0%完成系列,3.4%超过42天未接种。
  • 错过第二剂比例在辖区间差异大(0.0%-9.1%),AI/AN人群和16-44岁较高。
  • 第二剂接种者中95.6%在推荐间隔内完成,辖区范围79.0%-99.9%。

核心结论

  • 多数接种者按推荐完成第二剂,但错过第二剂和间隔延迟存在辖区与人群差异。

研究设计与样本

  • 对2020年12月14日至2021年2月14日启动接种且数据截至2021年2月20日上报CDC的人群进行两项分析。

主要发现

  • 错过第二剂比例辖区范围0.0%-9.1%,非西班牙裔美洲印第安/阿拉斯加原住民为5.1%,16-44岁为4.0%。

关键数值与推荐

  • 推荐间隔:辉瑞-BioNTech为21天,Moderna为28天;不可避免延迟时允许至42天。
  • 本研究推荐间隔定义:辉瑞-BioNTech为17-25天,Moderna为24-32天。
  • 有足够时间定义:截至2021年2月14日,辉瑞-BioNTech第一剂后>25天或Moderna第一剂后>32天。

临床怎么用

  • 公共卫生官员应识别并解决完成新冠疫苗接种系列的障碍,确保社区公平覆盖。
  • 可采取策略包括在第一剂接种时预约第二剂并发送第二剂就诊提醒。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In December 2020, two COVID-19 vaccines (Pfizer-BioNTech and Moderna) received Emergency Use Authorization from the Food and Drug Administration.*,† Both vaccines require 2 doses for a completed series. The recommended interval between doses is 21 days for Pfizer-BioNTech and 28 days for Moderna; however, up to 42 days between doses is permissible when a delay is unavoidable.§ Two analyses of COVID-19 vaccine administration data were conducted among persons who initiated the vaccination series during December 14, 2020-February 14, 2021, and whose doses were reported to CDC through February 20, 2021. The first analysis was conducted to determine whether persons who received a first dose and had sufficient time to receive the second dose (i.e., as of February 14, 2021, >25 days from receipt of Pfizer-BioNTech vaccine or >32 days from receipt of Moderna vaccine had elapsed) had received the second dose. A second analysis was conducted among persons who received a second COVID-19 dose by February 14, 2021, to determine whether the dose was received during the recommended dosing interval, which in this study was defined as 17-25 days (Pfizer-BioNTech) and 24-32 days (Moderna) after the first dose. Analyses were stratified by jurisdiction and by demographic characteristics. In the first analysis, among 12,496,258 persons who received the first vaccine dose and for whom sufficient time had elapsed to receive the second dose, 88.0% had completed the series, 8.6% had not received the second dose but remained within the allowable interval (≤42 days since the first dose), and 3.4% had missed the second dose (outside the allowable interval, >42 days since the first dose). The percentage of persons who missed the second dose varied by jurisdiction (range = 0.0%-9.1%) and among demographic groups was highest among non-Hispanic American Indian/Alaska Native (AI/AN) persons (5.1%) and persons aged 16-44 years (4.0%). In the second analysis, among 14,205,768 persons who received a second dose, 95.6% received the dose within the recommended interval, although percentages varied by jurisdiction (range = 79.0%-99.9%). Public health officials should identify and address possible barriers to completing the COVID-19 vaccination series to ensure equitable coverage across communities and maximum health benefits for recipients. Strategies to ensure series completion could include scheduling second-dose appointments at the first-dose administration and sending reminders for second-dose visits.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Kriss JL, Reynolds LE, Wang A, et al. COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons - United States, December 14, 2020-February 14, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33735162. doi:10.15585/mmwr.mm7011e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。